Recognising the importance of chronic lung disease: a consensus statement from the Global Alliance for Chronic Diseases (Lung Diseases group)

Gould, Gillian Sandra; Hurst, John R.; Trofor, Antigona; Alison, Jennifer A.; Fox, Gregory J.; Kulkarni, Muralidhar M; Wheelock, Craig E.; Clarke, Matthew; Kumar, Ratika

doi:10.1186/s12931-022-02297-y

Cited by 12 publications

(5 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of these patients, 1.2 million were diagnosed with chronic obstructive pulmonary disease (COPD), which is the third leading cause of death worldwide [ 1 ], and >150,000 were diagnosed with interstitial lung disease (ILD). According to a recent Asthma + Lung UK report, the United Kingdom spends £11 billion (US $13.4 billion) on respiratory diseases each year, with 29% of that budget allocated to COPD [ 17 , 23 ]. Recent studies have demonstrated the importance of timely identification of exacerbations of COPD [ 24 - 26 ]; therefore, longitudinal measurement of symptoms and physiological parameters has the potential to allow for earlier detection [ 27 ].…”

Section: Introductionmentioning

confidence: 99%

“…Recent studies have demonstrated the importance of timely identification of exacerbations of COPD [ 24 - 26 ]; therefore, longitudinal measurement of symptoms and physiological parameters has the potential to allow for earlier detection [ 27 ]. There is currently an unmet need in the care of patients with respiratory diseases [ 23 , 28 ]. Patients with chronic respiratory diseases and those in the postdischarge period following hospitalization because of COVID-19 are particularly vulnerable, and little is known about the changes in their symptoms and physiological parameters [ 29 , 30 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating a Remote Monitoring Program for Respiratory Diseases: Prospective Observational Study

Althobiani,

Ranjan,

Jacob

et al. 2023

JMIR Form Res

View full text Add to dashboard Cite

Background Patients with chronic respiratory diseases and those in the postdischarge period following hospitalization because of COVID-19 are particularly vulnerable, and little is known about the changes in their symptoms and physiological parameters. Continuous remote monitoring of physiological parameters and symptom changes offers the potential for timely intervention, improved patient outcomes, and reduced health care costs. Objective This study investigated whether a real-time multimodal program using commercially available wearable technology, home-based Bluetooth-enabled spirometers, finger pulse oximeters, and smartphone apps is feasible and acceptable for patients with chronic respiratory diseases, as well as the value of low-burden, long-term passive data collection. Methods In a 3-arm prospective observational cohort feasibility study, we recruited 60 patients from the Royal Free Hospital and University College Hospital. These patients had been diagnosed with interstitial lung disease, chronic obstructive pulmonary disease, or post–COVID-19 condition (n=20 per group) and were followed for 180 days. This study used a comprehensive remote monitoring system designed to provide real-time and relevant data for both patients and clinicians. Data were collected using REDCap (Research Electronic Data Capture; Vanderbilt University) periodic surveys, Remote Assessment of Disease and Relapses–base active app questionnaires, wearables, finger pulse oximeters, smartphone apps, and Bluetooth home-based spirometry. The feasibility of remote monitoring was measured through adherence to the protocol, engagement during the follow-up period, retention rate, acceptability, and data integrity. Results Lowest-burden passive data collection methods, via wearables, demonstrated superior adherence, engagement, and retention compared with active data collection methods, with an average wearable use of 18.66 (SD 4.69) hours daily (77.8% of the day), 123.91 (SD 33.73) hours weekly (72.6% of the week), and 463.82 (SD 156.70) hours monthly (64.4% of the month). Highest-burden spirometry tasks and high-burden active app tasks had the lowest adherence, engagement, and retention, followed by low-burden questionnaires. Spirometry and active questionnaires had the lowest retention at 0.5 survival probability, indicating that they were the most burdensome. Adherence to and quality of home spirometry were analyzed; of the 7200 sessions requested, 4248 (59%) were performed. Of these, 90.3% (3836/4248) were of acceptable quality according to American Thoracic Society grading. Inclusion of protocol holidays improved retention measures. The technologies used were generally well received. Conclusions Our findings provide evidence supporting the feasibility and acceptability of remote monitoring for capturing both subjective and objective data from various sources for respiratory diseases. The high engagement level observed with passively collected data suggests the potential of wearables for long-term, user-friendly remote monitoring in respiratory disease management. The unique piloting of certain features such as protocol holidays, alert notifications for missing data, and flexible support from the study team provides a reference for future studies in this field. International Registered Report Identifier (IRRID) RR2-10.2196/28873

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Evaluating a Remote Monitoring Program for Respiratory Diseases: Prospective Observational Study

Althobiani,

Ranjan,

Jacob

et al. 2023

JMIR Form Res

View full text Add to dashboard Cite

show abstract

“…Chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and pulmonary hypertension are among the five disease areas with the highest global mortality and morbidity rates ( 76 ). With almost 300 million people affected, asthma is one of the most common respiratory diseases worldwide ( 77 ).…”

Section: Randomized Double-blind Placebo-controlled Human Clinical St...mentioning

confidence: 99%

Pycnogenol® French maritime pine bark extract in randomized, double-blind, placebo-controlled human clinical studies

Weichmann,

Rohdewald

2024

Front. Nutr.

View full text Add to dashboard Cite

Pycnogenol® French maritime pine bark extract is a well-known and thoroughly studied patented extract from the bark of Pinus pinaster Ait. ssp. Atlantica. In 39 randomized double-blind, placebo-controlled (RDP) human clinical trials including 2,009 subjects, Pycnogenol® French maritime pine bark extract supplementation for two weeks to six months has been shown to beneficially affect cardiovascular health, chronic venous insufficiency, cognition, joint health, skin health, eye health, women’s health, respiratory health and allergies, oral health and sports performance. The mechanisms of action that can explain the respective effects on different conditions in the human body are discussed as well. As investigated in several in vitro, in vivo and in clinical studies, Pycnogenol® French maritime pine bark extract showed antioxidative effects, anti-inflammatory abilities, beneficial effects on endothelial function and reinforcing effects on the extracellular matrix. The present review aims to give a comprehensive overview of currently available “gold standard” RDP trials of Pycnogenol®’s benefits across various health domains compared to placebo. In addition, some of the processes on which the presented effects of Pycnogenol® French maritime pine bark extract are based will be elucidated and discussed. This broad overview of RDP studies on Pycnogenol® in different health domains can be used as a basis for further research on applications and mechanisms of this unique French maritime pine bark extract.

show abstract

“…Inhalation of various harmful toxins and microorganisms leads to the development of lung diseases. Lung diseases, including lung cancer, asthma, mycobacterium-based tuberculosis, COPD, and cystic fibrosis, are diseases that target the various regions of the lungs, particularly the airways [4][5][6]. Chronic inflammation typically elevates the susceptibility to debilitating lung conditions.…”

Section: Introductionmentioning

confidence: 99%

Spray-Dried Nanolipid Powders for Pulmonary Drug Delivery: A Comprehensive Mini Review

Abu Elella,

Al Khatib,

Al-Obaidi

2024

Pharmaceutics

View full text Add to dashboard Cite

Lung diseases have received great attention in the past years because they contribute approximately one-third of the total global mortality. Pulmonary drug delivery is regarded as one of the most appealing routes to treat lung diseases. It addresses numerous drawbacks linked to traditional dosage forms. It presents notable features, such as, for example, a non-invasive route, localized lung drug delivery, low enzymatic activity, low drug degradation, higher patient compliance, and avoiding first-pass metabolism. Therefore, the pulmonary route is commonly explored for delivering drugs both locally and systemically. Inhalable nanocarrier powders, especially, lipid nanoparticle formulations, including solid-lipid and nanostructured-lipid nanocarriers, are attracting considerable interest in addressing respiratory diseases thanks to their significant advantages, including deep lung deposition, biocompatibility, biodegradability, mucoadhesion, and controlled drug released. Spray drying is a scalable, fast, and commercially viable technique to produce nanolipid powders. This review highlights the ideal criteria for inhalable spray-dried SLN and NLC powders for the pulmonary administration route. Additionally, the most promising inhalation devices, known as dry powder inhalers (DPIs) for the pulmonary delivery of nanolipid powder-based medications, and pulmonary applications of SLN and NLC powders for treating chronic lung conditions, are considered.

show abstract

Recognising the importance of chronic lung disease: a consensus statement from the Global Alliance for Chronic Diseases (Lung Diseases group)

Cited by 12 publications

References 62 publications

Evaluating a Remote Monitoring Program for Respiratory Diseases: Prospective Observational Study

Evaluating a Remote Monitoring Program for Respiratory Diseases: Prospective Observational Study

Pycnogenol® French maritime pine bark extract in randomized, double-blind, placebo-controlled human clinical studies

Spray-Dried Nanolipid Powders for Pulmonary Drug Delivery: A Comprehensive Mini Review

Contact Info

Product

Resources

About